Search company, investor...

Copernicus Therapeutics

Founded Year



Grant | Alive

Total Raised


Last Raised

$14.7M | 1 yr ago

About Copernicus Therapeutics

Copernicus Therapeutics is a clinical-stage biopharmaceutical company in the emerging field of precision medicine and gene therapy. The company is based in Cleveland, Ohio.

Headquarters Location

11000 Cedar Avenue Suite 145

Cleveland, Ohio, 44106,

United States


Missing: Copernicus Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Copernicus Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Copernicus Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Copernicus Therapeutics is included in 2 Expert Collections, including Renewable Energy.


Renewable Energy

4,037 items

This collection contains upstream and downstream solar companies, as well as those who manufacture and sell products that are powered by solar technology.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Copernicus Therapeutics Patents

Copernicus Therapeutics has filed 7 patents.

The 3 most popular patent topics include:

  • Driver distraction
  • Neuropsychological tests
  • Psychological testing
patents chart

Application Date

Grant Date


Related Topics




Road safety, Driver distraction, Neuropsychological tests, Psychological testing, Vehicle law


Application Date


Grant Date



Related Topics

Road safety, Driver distraction, Neuropsychological tests, Psychological testing, Vehicle law



Latest Copernicus Therapeutics News

Nucleic Acid Based Gene Therapy Market Research | Edition 2023 | Recent Developments and SWOT Analysis 2028

Jan 23, 2023

| Edition 2023 | Recent Developments and SWOT Analysis 2028 News Provided By Share This Article Douglas Insights Copernicus Therapeutics; Moderna Inc., Wave Life Sciences; Protagonist Therapeutics; Transgene are some of the major key players. The use of nucleic acid molecules (such as DNA or RNA) to treat or prevent diseases by altering the expression of specific genes is known as nucleic acid-based gene therapy. These therapies have the potential to provide long-term or even permanent treatment for genetic disorders, and early clinical trials for a variety of conditions, including inherited diseases, cancer, and infectious diseases, have yielded promising results. The market for nucleic acid-based gene therapy is a rapidly expanding field within the pharmaceutical industry. The global nucleic acid-based gene therapy market was valued at $2.2 billion in 2019 and is expected to reach $10.7 billion by 2027, growing at a CAGR (compound annual growth rate) of 36.46% from 2020 to 2027. Rising government and corporate financial support is expected to drive demand for nucleic acid-based gene therapy. Nucleic acid therapeutics are synthetic versions of naturally occurring acids or proteins that regulate genetic expression. The foundation of these classes of drugs is genetic profiling and molecular target identification. Nucleic acid medication has a higher potential for treating these diseases because it targets the genetic basis of the disease and has a permanent cure. Nucleic Acid Based Gene Therapy Market Growth Drivers and Risks The nucleic acid-based gene therapy market is being driven by several factors, including: Genetic diseases are becoming more common: Many genetic diseases, such as cystic fibrosis and sickle cell anaemia, are caused by mutations in a single gene. Gene therapies based on nucleic acids have the potential to treat these diseases by inserting a healthy copy of the gene into cells, restoring normal function. Researchers are constantly developing new and improved techniques for delivering gene therapies, such as the use of viral vectors to introduce genetic material into cells. There are several risks associated with the market for nucleic acid-based gene therapy, Before gene therapies can be marketed to the general public, they must undergo extensive testing and regulatory approval. This can be a lengthy and costly process, and not all therapies that enter clinical trials are approved. Because gene therapies are still in their early stages, there is a risk that unexpected side effects or long-term consequences will emerge as the therapies become more widely used. Nucleic Acid Based Gene Therapy Market Key players Copernicus Therapeutics; Moderna Inc., Wave Life Sciences; Protagonist Therapeutics; Transgene are some of the major key players. Check out the detailed TOC, Tables, and Figures with Charts for exclusive data, information, vital statistics, trends, and competitive landscape details: Nucleic Acid Based Gene Therapy Market Segmentations By Nucleic Acid Technology Reasons Why You Should Buy This Report • The Nucleic Acid Based Gene Therapy Market report is a compilation of data from different sources and has been put together in a way that makes it easy for the reader to understand. • It covers a wide range of topics, including Nucleic Acid Based Gene Therapy Market current trends, market size, and forecasted growth. • The Nucleic Acid Based Gene Therapy Market report provides valuable insights that can help you make informed decisions about your business. The data is accurate and up-to-date, so you can trust the information presented. • This Nucleic Acid Based Gene Therapy Market report is an excellent resource for business owners who are looking to gain an understanding of the market landscape and potential opportunities. • It will help you identify growth sectors and predict future trends of Nucleic Acid Based Gene Therapy Market Table of content 2. Table of Contents Follow Douglas Insights for More Industry Updates- @ LinkedIn & Twitter About Douglas Insights- Douglas Insights UK limited is the first company to provide comparison of market research reports by Table of content, price, ratings and number of pages. We understand the value of time. Productivity and efficiency are possible when you take prompt and assured decisions. With our advanced algorithm, filters, and comparison engine, you can compare your preferred reports simultaneously, based on publisher rating, published date, price, and list of tables. Our data portal enables you to find and review the reports from several publishers. You can evaluate numerous reports on the same screen and select the sample for your best match. Office- Isle of Man IM4 5HA, Isle of Man Email-

Copernicus Therapeutics Frequently Asked Questions (FAQ)

  • When was Copernicus Therapeutics founded?

    Copernicus Therapeutics was founded in 1995.

  • Where is Copernicus Therapeutics's headquarters?

    Copernicus Therapeutics's headquarters is located at 11000 Cedar Avenue, Cleveland.

  • What is Copernicus Therapeutics's latest funding round?

    Copernicus Therapeutics's latest funding round is Grant.

  • How much did Copernicus Therapeutics raise?

    Copernicus Therapeutics raised a total of $28.95M.

  • Who are the investors of Copernicus Therapeutics?

    Investors of Copernicus Therapeutics include National Institutes of Health and Vivo Capital.

  • Who are Copernicus Therapeutics's competitors?

    Competitors of Copernicus Therapeutics include Bossa Nova Vision, Standard Solar, Trina Solar, Ice Energy, Clean Power Finance and 13 more.

Compare Copernicus Therapeutics to Competitors

Octillion Corporation

Octillion Corp., together with its wholly owned subsidiaries, is a technology incubator focused on the identification, acquisition, development, and commercialization of alternative and renewable energy technologies. Through established relationships with universities, research institutions, government agencies and start-up companies, the company strive to identify technologies and business opportunities on an edge of innovation that have the potential of serving and unmet market needs. nOnce a technology has been identified, the company fund the research and development activities relating to the technology with the intention of ultimately, if warranted, licensing, commercializing and marketing the subject technology, either through internal resources, collaborative agreements or otherwise. Unique to the company's business model is the use of established research infrastructure owned by the various organizations the company deal with, saving us capital which would otherwise be required for such things as land and building acquisition, equipment and furniture purchases, and other incidental start up costs. As a result, the company are able to conduct research in development. nnAmong the company's current research and development activities is the development of a patent-pending technology that could adapt existing home and office glass windows into ones capable of generating electricity from solar energy without losing transparency or requiring major changes in manufacturing infrastructure. The company are also developing a system to harness the kinetic energy of vehicles in motion as part of a broader effort to enhance the sustainability and energy efficiency of transportation infrastructures and systems.

Camstar Systems Logo
Camstar Systems

Camstar Systems provides enterprise manufacturing execution and quality management software solutions to a global clientele. It enables global networks of manufacturers, brand owners, and suppliers to produce the highest quality products quickly and efficiently. The company was founded in 1984 and is based in Charlotte, North Carolina. Camstar Systems was acquired by Samsung.


Anteos is a company that received a SBIR Phase II grant for a project entitled: Relief-Free Infrared Diffractive Optics Based on Semiconductor Materials. Their award is funded under the American Recovery and Reinvestment Act of 2009 (Public Law 111-5) and their project will develop a new generation of relief-free thin-plate components of diffractive optics operating in the infrared region of spectrum. The diffractive optics employs volume phase holographic structures, which are optically recorded in semiconductor materials transparent at the infrared wavelengths using proprietary process of photo-modification for producing dramatic change of the material refractive index under illumination with low intensity light. Phase I of this project proved feasibility of the proposed concept by demonstrating photo modification of ZnSe infrared material and fabricating the first model components. The developed technology can be immediately applied to fabrication of diffractive optics, volume phase holographic gratings, and phase retardation plates for wavelengths up to 1.9 m, as well as antireflection layers for wavelengths up to 8 m. In Phase II project the technology will be optimized and applied to fabrication of the prototype components of infrared diffractive optics operating at longer wavelengths, including the important wavelength of CO2 laser 10.6 m and windows of atmospheric transparency 3-5 and 8-12 m. The developed photo-modification process is highly adaptable and creates a rich technology platform for fabrication of a broad range of products for a large variety of markets. Successful implementation of this technology will result in a new generation of high efficiency relief-free infrared diffractive optics and sub-wavelength components, including diffraction gratings, beam splitters, beam shapers, semiconductor materials with artificial birefringence, phase retardation plates and wave plates. The relief-free components of infrared diffractive optics based on semiconductor materials are capable to withstand high light intensities and perform complicated light management functions. Another important application is the fabrication of highly stable anti-reflection (AR) layers on infrared semiconductor optics. The market for infrared diffractive optics includes defense and airspace industry, laser industry, spectral devices, sensors and detectors, night vision optics, industrial process control, material processing, cutting and welding, environmental monitoring, medical diagnostics and surgery. Anteos is a company that received a SBIR Phase II grant for a project entitled: High-Efficiency Nanocomposite Photovoltaics and Solar Cells. Their project is focused on development of an innovative technology for fabrication of high-efficiency thin film nanocomposite photovoltaic materials and solar cells taking advantage of the recently discovered effect of carrier multiplication in semiconductor nanocrystals. The proposed concept employs smart design of the solar cells providing fast and effective spatial separation of electrons and holes photo-generated in the nanocrystals. The proposed reach nanotechnology platform solves the challenging problem of electrical communications with nanoscale objects, such as nanocrystals, nanorods, nanowires, nanotubes, etc. It can be employed for development of many other nanocomposite optoelectronic devices having numerous commercial and military applications. If successful the development of new generation of high-efficiency photovoltaic materials and solar cells based on the demonstrated technology will have broad impact on the entire solar energy industry resulting in considerable energy savings and environmental protection. The technology has great commercialization potential and niche market. The proposed all-inorganic, high-efficiency, thin film, flexible nanostructured photovoltaic materials and solar cells, which can operate in extreme environment conditions and offer significant mass and volume savings, are ideally suitable for numerous applications, including power generating residential rooftops, power supplies for utility grid, emergency signals and telephones, water pumps, activate switches, battery chargers, residential and commercial lighting, etc.

Anaxtal Silicon

Anaxtal Silicon is Anaxtal Silicon has developed the "Witter Green Cycle" for manufacturing a grade of silicon specifically tailored for the solar photovoltaic wafer and module manufacturers at a low cost.

Orb Energy Logo
Orb Energy

Orb Energy is a residential and commercial solar system integrator and financier and installer. It manufactures its own range of solar photovoltaic panels and designs, installs, and services solar systems, along with providing critical finance for up to five years to its commercial and industrial customers. The company was founded in 2006 and is based in Bengaluru, India.

Greenfield Solar Logo
Greenfield Solar

PhotoVolt, Inc. was founded in 1994 by Bernard Sater, a former NASA Glenn Research Center scientist and inventor, with a vision to enable high intensity photovoltaic ("PV"‚) concentrator systems to achieve lower cost per watt than is possible with conventional photovoltaic technologies. PhotoVolt's cell technology has the potential for making PV power systems economically viable for widespread application and cost competitive with conventional fuels in large-scale global markets. Over the past 14 years, with the support of NASA Glenn Research Center , and the late Dr. Chandra Goradia, a renowned PV researcher at Cleveland State University, with US Department of Energy grants, Mr. Sater successfully proved the promise of his invention and introduced it to the market as a commercial product. In 2007, PhotoVolt management decided to accelerate development of the high intensity concentrator market by forming a new company called GreenField Steam & Electric Co. to develop and commercialize concentrator PV systems utilizing PhotoVolt's cell technology. The new company successfully raised seed money, developed a new concentrator design, made first sales, and secured the IP by filing for many patents. The Company aiming to bring to market a high intensity concentrating PV system named StarGen a solution that is ideally suited to leverage the strengths of the PhotoVolt cell, while delivering "free"‚ thermal energy . This system is designed to make maximum use of off-the-shelf components and materials, holding the promise to produce solar energy at lower price points. In 2008, PhotoVolt, Inc. and GreenField Steam & Electric Co. agreed to merge, becoming GreenField Solar The Company, based near Cleveland Ohio, USA, intends to license its technology in the future. Management is working to raise additional capital to scale up production capacity in 2009 and beyond.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.